{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["316"],"submitter":["Filippatos F"],"pubmed_abstract":["<h4>Background</h4>SARS-CoV-2 Spike protein Receptor Binding Domain neutralizing antibodies (NAbs-RBD) inhibit the viral binding to angiotensin-converting enzyme 2 (ACE2) receptors. We compared an ELISA and a fluorescence immunochromatography (FIC) method in NAbs-RBD detection after COVID-19 immunization.<h4>Method</h4>Serum samples from healthcare workers (HCWs) vaccinated with BNT162b2 were collected one and four months after the second dose. NAbs-RBD (%) detection was performed using ELISA cPass™ (FDA approved) and FIC n-AbCOVID-19® assays.<h4>Results</h4>Samples from 200 HCWs [median age (IQR): 45(35-53)] were tested with both assays. There was a good qualitative agreement between the two methods [AUC: 0.92(95%C.I.: 0.89-0.94, P-value:0.007)]. NAbs-RBD (%), one and four months after im"],"journal":["Journal of virological methods"],"pagination":["114728"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10074729"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity."],"pmcid":["PMC10074729"],"pubmed_authors":["Michos A","Filippatos F","Tatsi EB","Papagiannopoulos C","Syriopoulou V"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity.","description":"<h4>Background</h4>SARS-CoV-2 Spike protein Receptor Binding Domain neutralizing antibodies (NAbs-RBD) inhibit the viral binding to angiotensin-converting enzyme 2 (ACE2) receptors. We compared an ELISA and a fluorescence immunochromatography (FIC) method in NAbs-RBD detection after COVID-19 immunization.<h4>Method</h4>Serum samples from healthcare workers (HCWs) vaccinated with BNT162b2 were collected one and four months after the second dose. NAbs-RBD (%) detection was performed using ELISA cPass™ (FDA approved) and FIC n-AbCOVID-19® assays.<h4>Results</h4>Samples from 200 HCWs [median age (IQR): 45(35-53)] were tested with both assays. There was a good qualitative agreement between the two methods [AUC: 0.92(95%C.I.: 0.89-0.94, P-value:0.007)]. NAbs-RBD (%), one and four months after im","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-18T16:30:10.487Z","creation":"2025-02-19T04:16:18.278Z"},"accession":"S-EPMC10074729","cross_references":{"pubmed":["37028561"],"doi":["10.1016/j.jviromet.2023.114728"]}}